CYP3A11 inhibitors constitute a diverse category of chemical entities intricately designed to exert control over the enzymatic activity of CYP3A11, a pivotal member of the cytochrome P450 enzyme family. These inhibitors function through a nuanced interaction that involves precise binding to the catalytic or allosteric sites of the CYP3A11 enzyme. This binding event initiates a cascade of molecular changes that disrupt the enzyme's customary catalytic function, inducing a state of suppressed activity. As a consequence, the biotransformation of an array of substrates, ranging from pharmacologically active compounds to endogenous molecules and even potential toxins, is hindered.
The intricacy of the interaction dynamics yields various levels of inhibition, potentially altering the kinetics of enzyme-substrate interactions. Depending on the nature of the chemical interaction, CYP3A11 inhibitors can operate either reversibly or irreversibly, where the latter form entails a longer-lasting and potentially more profound effect. Researchers endeavor to unravel the minutiae of inhibitor binding mechanisms, exploring the structural determinants that underpin the interaction's specificity, affinity, and kinetics.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole is a known inhibitor of CYP3A enzymes, including CYP3AI can significantly decrease the activity of CYP3A11, potentially leading to altered potential drug metabolism. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $76.00 $139.00 | 23 | |
Itraconazole inhibits CYP3A11 activity. | ||||||
Clarithromycin | 81103-11-9 | sc-205634 sc-205634A | 100 mg 250 mg | $75.00 $120.00 | 1 | |
This has been shown to inhibit CYP3A enzymes, including CYP3A11, which can influence the potential metabolism of drugs that are substrates of these enzymes. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $312.00 | 9 | |
This has been shown to inhibit CYP3A enzymes, potentially affecting the potential metabolism of other drugs. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
This calcium channel blocker can inhibit CYP3A enzymes, potentially affecting the potential metabolism of drugs that are metabolized by CYP3A11. | ||||||
Erythromycin | 114-07-8 | sc-204742 sc-204742A sc-204742B sc-204742C | 5 g 25 g 100 g 1 kg | $56.00 $240.00 $815.00 $1305.00 | 4 | |
Erythromycin, has been associated with CYP3A inhibition, which can impact the potential metabolism of various drugs. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
This can inhibit CYP3A enzymes, leading to potential drug interactions and altered metabolism. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine, a histamine H2 receptor antagonist, has been reported to inhibit CYP3A enzymes. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $53.00 $84.00 | 14 | |
Fluconazole can also inhibit CYP3A enzymes, influencing potential drug metabolism. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
This calcium channel blocker can inhibit CYP3A11 and other CYP3A enzymes. |